Cellectis Bioresearch Announces Availability of Research Kits Through New Online E-Store

PARIS, Sept. 27 /PRNewswire/ -- Cellectis bioresearch, the specialist in genome customization and subsidiary of Cellectis (Alternext: ALCLS), is pleased to announce the launch of its e-store, with approximately one hundred ready-to-use products available for sale online via a new functional and intuitive website.

Launched in 2008, Cellectis bioresearch develops and markets a full line of targeted integration kits, which offer a simple, effective means of using Cellectis meganuclease technologies.

The new Cellectis bioresearch website includes an e-store where its cGPS® (cellular Genome Positioning System) and cGPS® Custom kits - which include a cell line, an integration matrix and a meganuclease – may be purchased. If desired, each component may also be bought individually. Cellectis bioresearch offers a vast line of integration matrices, making it possible to choose the quantity and quality of the specific protein to be expressed.

On the site, these products are categorized according to the three main Cellectis bioresearch markets:

• Drug discovery
• Protein production
• Functional genomics

To make the products even easier to use, Cellectis bioresearch has published a series of documents corresponding to each product, which include illustrated explanations, scientific results as well as detailed and validated protocols.

"The launch of a website with online purchasing capacities was a vital step in improving researchers' access to our meganuclease technology," explains Luc Selig, VP Sales & Marketing at Cellectis bioresearch. "Our product offering has expanded rapidly, and we now market over one hundred different products on three target markets."

For more information, log on to www.cellectis-bioresearch.com

About Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on meganucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies.

More information at www.cellectis-bioresearch.com

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools - meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over Euro 70 million in funding since inception.

More information at www.cellectis.com

Follow Cellectis on Twitter at www.twitter.com/cellectis

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa n 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

SOURCE Cellectis